Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$38.39 USD
+1.21 (3.25%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $38.37 -0.02 (-0.05%) 4:50 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Revolution Medicines, Inc. has a market cap of $6.93B, which represents its share price of $37.18 multiplied by its outstanding shares number of 186.27M. As a mid-cap company, RVMD's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RVMD 38.39 +1.21(3.25%)
Will RVMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RVMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVMD
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
RVMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for RVMD
What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings
Revolution Medicines Inc (RVMD) Announces Upcoming Q2 2025 Financial Results Release | RVMD ...
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on ...
Revolution Medicines Inc (RVMD) Unveils Breakthrough in Targeted Cancer Therapy | RVMD stock news
Revolution Medicines (RVMD) Publishes Breakthrough on Zoldonrasib Targeting RAS G12D | RVMD ...